A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL346 in Healthy Caucasian and Japanese Adult Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs CSL 346 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors CSL
- 15 Nov 2017 Status changed from recruiting to not yet recruiting.
- 10 Feb 2017 According to a CSL media release, this trial is expected to initiate in 2017.
- 07 Dec 2016 New trial record